[go: up one dir, main page]

CO2022015823A2 - Derivados de n-(piperidin-4-il)benzamida de acción luminal - Google Patents

Derivados de n-(piperidin-4-il)benzamida de acción luminal

Info

Publication number
CO2022015823A2
CO2022015823A2 CONC2022/0015823A CO2022015823A CO2022015823A2 CO 2022015823 A2 CO2022015823 A2 CO 2022015823A2 CO 2022015823 A CO2022015823 A CO 2022015823A CO 2022015823 A2 CO2022015823 A2 CO 2022015823A2
Authority
CO
Colombia
Prior art keywords
luminal
piperidin
acting
benzamide derivatives
compounds
Prior art date
Application number
CONC2022/0015823A
Other languages
English (en)
Inventor
Tony S Gibson
Steve Swann
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2022015823A2 publication Critical patent/CO2022015823A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de Fórmula 1, , y sales farmacéuticamente aceptables de estos, en donde m, R1, R2, R3, R4, R5, R6, X1, X2, X3 y X4 se definen en la memoria descriptiva. Esta descripción también hace referencia a materiales y métodos para la preparación de compuestos de Fórmula 1, a composiciones farmacéuticas que los contienen y a su uso para el tratamiento de enfermedades, trastornos y afecciones asociados con el receptor 5-HT4.
CONC2022/0015823A 2020-05-04 2022-11-02 Derivados de n-(piperidin-4-il)benzamida de acción luminal CO2022015823A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019829P 2020-05-04 2020-05-04
PCT/US2021/030493 WO2021225968A1 (en) 2020-05-04 2021-05-03 Luminally-acting n-(piperidin-4-yl)benzamide derivatives

Publications (1)

Publication Number Publication Date
CO2022015823A2 true CO2022015823A2 (es) 2022-11-18

Family

ID=76060006

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0015823A CO2022015823A2 (es) 2020-05-04 2022-11-02 Derivados de n-(piperidin-4-il)benzamida de acción luminal

Country Status (19)

Country Link
US (1) US20230158010A1 (es)
EP (1) EP4146625B1 (es)
JP (1) JP7753254B2 (es)
KR (1) KR20230005893A (es)
CN (1) CN115515933A (es)
AR (1) AR122005A1 (es)
AU (1) AU2021266690A1 (es)
BR (1) BR112022022184A2 (es)
CA (1) CA3182379A1 (es)
CL (1) CL2022003067A1 (es)
CO (1) CO2022015823A2 (es)
EC (1) ECSP22091230A (es)
IL (1) IL297456A (es)
MX (1) MX2022013745A (es)
MY (1) MY210588A (es)
PE (1) PE20231375A1 (es)
PH (1) PH12022552956A1 (es)
TW (1) TWI905181B (es)
WO (1) WO2021225968A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CR20220559A (es) 2020-05-04 2023-08-18 Vigil Neuroscience Inc Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
SK30294A3 (en) * 1991-09-12 1994-12-07 Smithkline Beecham Plc Antagonists of 5-ht4 receptors
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
JPH111472A (ja) * 1996-04-30 1999-01-06 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体及びそれを含有する医薬組成物
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW548103B (en) * 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US6696468B2 (en) * 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
KR100976063B1 (ko) * 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
TW201014592A (en) * 2008-10-02 2010-04-16 Shanghai Hengrui Pharm Co Ltd Benzamide derivatives, preparing method and medicinal use thereof
WO2010062959A1 (en) * 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity

Also Published As

Publication number Publication date
KR20230005893A (ko) 2023-01-10
JP7753254B2 (ja) 2025-10-14
EP4146625A1 (en) 2023-03-15
AU2021266690A1 (en) 2022-11-10
TWI905181B (zh) 2025-11-21
IL297456A (en) 2022-12-01
CL2022003067A1 (es) 2023-07-14
CN115515933A (zh) 2022-12-23
PH12022552956A1 (en) 2024-02-26
US20230158010A1 (en) 2023-05-25
ECSP22091230A (es) 2023-02-28
AR122005A1 (es) 2022-08-03
JP2023525986A (ja) 2023-06-20
WO2021225968A1 (en) 2021-11-11
TW202208333A (zh) 2022-03-01
BR112022022184A2 (pt) 2023-01-17
CA3182379A1 (en) 2021-11-11
MX2022013745A (es) 2022-11-16
MY210588A (en) 2025-10-01
PE20231375A1 (es) 2023-09-07
EP4146625B1 (en) 2026-01-28

Similar Documents

Publication Publication Date Title
DOP2022000057A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
ECSP21080966A (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY31471A1 (es) Derivados bis-(sulfonilamino) en terapia 066
AR127050A1 (es) Compuestos espirocíclicos
ECSP22082217A (es) Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida
ECSP20062464A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
CO2022015823A2 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
CO2024014680A2 (es) Derivados de n-(pirrolidin-3-il o piperidin-4-il)acetamida
CO2024017138A2 (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
ECSP22082219A (es) Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina
CO2025011205A2 (es) Derivados de 1-amino-4-fenilftalazina útiles para el tratamiento de enfermedades neurodegenerativas
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
CO2023000117A2 (es) Derivados de sulfona
AR124720A1 (es) Derivados de pirazolamida
AR134054A1 (es) Derivados de n-(1-(aminometil)ciclopropil)(aril o heteroaril)carboxamida
AR134411A1 (es) Compuestos de uracilo
AR132037A1 (es) Derivados de piridazinil amino como inhibidores del receptor alk5
AR049638A1 (es) Derivados de benzileter, su elaboracion, su uso para preparar agentes farmaceuticos y composicion farmaceutica
ECSP972047A (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos
ECSP993127A (es) Derivados de dihidrobenzodioxina carboxamida y cetona
AR040908A1 (es) S-(+) -3- ((1-(2-(2,3-dihidro-1hindol3il) etil) 3,6-dihidro- 2h- piridin-4-il))-6-cloro-1h-indol, sales de adicion de acido del mismo y composicion farmaceutica